Drug Trial Radar · NCT02224157
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma
Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,215
Actual
Start
Nov 28, 2014
Primary completion
Aug 16, 2017
Study completion Aug 16, 2017
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test if Symbicort (budesonide/formoterol) Turbuhaler is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort 'as needed' will be compared with Pulmicort (budesonide) Turbuhaler twice daily plus terbutaline Turbuhaler 'as needed'
Conditions
- Asthma
Interventions
budesonide/formoterol 'as needed' + budesonide placebo bidDrug
Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
budesonode bid + terbutaline 'as needed'Drug
Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Severe Asthma Exacerbation Rate - Non-inferiority AnalysisTime frame: up to 52 weeks
- Annual Severe Asthma Exacerbation Rate - Superiority AnalysisTime frame: up to 52 weeks
Locations
340 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Sydney, Australia
Research Site
Botucatu, Brazil
Research Site
Florianópolis, Brazil
Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Salvador, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Sorocaba, Brazil
Research Site
Blagoevgrad, Bulgaria
Research Site
Pernik, Bulgaria
Research Site
Petrich, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Razlog, Bulgaria
Research Site
Sliven, Bulgaria
Research Site
Smolyan, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vidin, Bulgaria
Research Site
Yambol, Bulgaria
Research Site
Curicó, Chile
Research Site
Quillota, Chile
Research Site
Santiago, Chile
Research Site
Santiago, Chile
Showing 40 of 340 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.